Km Biologics Co., Ltd.

Ryo Yamaue

Masaharu Torikai

Kazuhiko Kimachi

Kazuyuki Ikeda

Hiroaki Mori

Motoharu Abe

Hiroto Onuma

Yukari Tsurudome

Akihiro Watanabe

Yuki Ohara

Mihoko Matsuo

Satoshi Kamakura

A novel vaccine antigen for prevention of Respiratory Syncytial Virus (RSV) infection is created which surpasses conventional vaccines comprising as an antigen RSV F protein alone in view of efficacy and/or safety. A vaccine is prepared which comprises as an antigen a RSV F/G chimeric protein wherein a portion of RSV F protein as a basic structure is replaced with a whole or a portion of Conserved Central Domain sequence of RSV G protein or wherein a whole or a portion of Conserved Central Domain sequence of RSV G is added to the basic structure. As a result of assessment of both efficacy and safety, a vaccine comprising as an antigen the F/G chimeric protein of the present invention confirmed to be more excellent than a vaccine comprising as an antigen RSV F protein alone in view of efficacy and/or safety.

RSV F/G chimeric vaccine

The present invention relates to a vaccine containing fixed virus particles, wherein a summed fever response of three rabbits to the fixed virus particles in a pyrogen test is less than 80% based on a summed fever response of three rabbits to original virus particles of the fixed virus particles or corresponding inactivated virus particles.

Vaccine containing immobilized virus particles

Growing community of inventors

Kikuchi, Japan

Ryo Yamaue